ANVS Annovis Bio, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1477845 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-107.9%
TTM EPS YoY-8.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-455.9%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets340.5%
Debt / equity—
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.08x
Accruals ratio36.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $15.78M | $12.01M | $16.72M | $8.75M | $6.29M | $5.16M | $5.01M | $5.00M |
| SG&A expense | $1.19M | $2.37M | $1.29M | $955,151 | $1.14M | $1.11M | $1.27M | $1.74M |
| Operating income | -$16.97M | -$14.38M | -$18.01M | -$9.71M | -$7.43M | -$6.27M | -$6.28M | -$6.73M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$9.46M | -$14.82M | -$17.61M | -$9.83M | -$7.26M | -$6.22M | -$5.54M | -$5.86M |
| EPS (basic) | -0.22 | -0.40 | -0.63 | — | -0.37 | -0.32 | -0.32 | — |
| EPS (diluted) | -0.22 | -0.40 | -0.63 | — | -0.37 | -0.32 | -0.32 | — |
| Weighted avg. shares (diluted) | 42.63M | 37.52M | 27.85M | — | 19.69M | 19.49M | 17.43M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.82M | $18.73M | $14.22M | $19.53M | $15.29M | $17.13M | $22.24M | $10.55M |
| Total assets | $5.50M | $22.04M | $16.24M | $21.08M | $17.19M | $21.45M | $26.74M | $13.93M |
| Current liabilities | $6.26M | $6.36M | $12.79M | $3.64M | $3.73M | $2.81M | $2.50M | $3.88M |
| Total liabilities | $18.74M | $26.29M | $13.12M | $4.23M | $4.03M | $3.12M | $2.68M | $4.62M |
| Shareholders' equity | -$13.23M | -$4.25M | $3.13M | $16.85M | $13.16M | $18.33M | $24.05M | $9.31M |
| Shares outstanding | 42.69M | 42.61M | 28.54M | 27.20M | 20.19M | 19.49M | 19.49M | 14.14M |
| Cash flow statement | ||||||||
| Operating cash flow | -$16.04M | -$21.91M | -$9.01M | -$8.93M | -$3.49M | -$5.11M | -$8.10M | -$8.29M |
| Financing cash flow | $127,827 | $26.42M | $3.70M | $13.17M | $1.64M | $0 | $19.78M | $6.20M |
| Stock-based compensation | $355,102 | $1.61M | $182,823 | $356,524 | $444,647 | $496,618 | $499,887 | $1.48M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.